Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Opus Genetics Inc
IRD
Healthcare
Biotechnology
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1...
to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease cau...
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:IRD)
New Post
View:
Posts & Comments
Threaded Posts
(223)
•••
joebravo
X
Comment by
joebravo
on Sep 27, 2023 8:25am
RE:FDA PDUFA Date September 28, 2023
And there you have it. FDA Approval of Nyxol RM, which will be manufactured and sold under the name RYZUMVI by Viatris starting first half of 2024. Ocuphire will now receive their first
...more
(223)
•••
joebravo
X
Post by
joebravo
on Sep 13, 2023 8:57am
FDA PDUFA Date September 28, 2023
Not sure why this board has very little following, but this little company with a small float of 21 million shares is about to receive a FDA decision in 2 weeks which could potentially double their
...more
(1384)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 24, 2021 10:42am
OCUP....early a.m runner up on NR
You better be looking both ways on this ...... THere is a Shelf Offering on the table This will come back to bite you real hard JMHO
(187)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Feb 14, 2020 11:58am
added more of this one
using dollar cost averaging ,or DCA,for this one,and yes it was a $600 stock but that was 20 years ago,so glta shareholders.
(36)
•••
Teccing
X
Comment by
Teccing
on Feb 11, 2020 6:16pm
RE:it's a buy today for me
once $600
(187)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Feb 11, 2020 2:52pm
it's a buy today for me
got it this morning at $3.25 per share,it is making a comeback,so glta shareholders.
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
Western Star Resources Expands Its Past Producing Rowland Tungsten Property by 170%
The Metals Royalty Company Commences Trading on the Nasdaq Capital Market Under the Symbol "TMCR"
Airborne geophysical survey commences at Haldane Silver Project at Keno Hill Silver District, Yukon
Blue Sky Uranium Commences Diamond Drilling at Ivana East Target at Amarillo Grande District
Podcasts